A recent paper offered a theory on how psilocybin works to treat depression. Before long, there were memes and accusations of unprofessionalism.
Pharmaceutical patents are used to extend monopolies, leading to high drug prices, and reduced access. Will the psychedelic industry follow suit?
In his mid-50s, a depressed, Yale-trained scientist took a potent psychedelic, saw God, and set out to spread the word. Within two years, he was dead.
Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.
“We’ve had some very bad fights in our relationship but facing these issues and talking about them after tripping together made us realise how grateful we are for each other.”
The study of false—sober—insights teaches us to be wary of accepting every realization from psychedelic trips without critical thinking.
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.